acetaminophen; benzhydrocodone hydrochloride - Profile

What are the generic sources for acetaminophen; benzhydrocodone hydrochloride and what is the scope of freedom to operate?

Acetaminophen; benzhydrocodone hydrochloride is the generic ingredient in one branded drug marketed by Zevra Therap and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Acetaminophen; benzhydrocodone hydrochloride has thirty-five patent family members in twenty countries.

Summary for acetaminophen; benzhydrocodone hydrochloride

International Patents:	35
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for acetaminophen; benzhydrocodone hydrochloride

Constraining patent/regulatory exclusivity:

8,461,137

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for acetaminophen; benzhydrocodone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zevra Therap	APADAZ	acetaminophen; benzhydrocodone hydrochloride	TABLET;ORAL	208653-002	Jan 4, 2019		DISCN	Yes	No	9,132,125		Y	Y
Zevra Therap	APADAZ	acetaminophen; benzhydrocodone hydrochloride	TABLET;ORAL	208653-002	Jan 4, 2019		DISCN	Yes	No	8,828,978		Y
Zevra Therap	APADAZ	acetaminophen; benzhydrocodone hydrochloride	TABLET;ORAL	208653-002	Jan 4, 2019		DISCN	Yes	No	8,748,413		Y	Y
Zevra Therap	APADAZ	acetaminophen; benzhydrocodone hydrochloride	TABLET;ORAL	208653-002	Jan 4, 2019		DISCN	Yes	No	9,549,923		Y	Y
Zevra Therap	APADAZ	acetaminophen; benzhydrocodone hydrochloride	TABLET;ORAL	208653-002	Jan 4, 2019		DISCN	Yes	No	8,461,137		Y	Y

International Patents for acetaminophen; benzhydrocodone hydrochloride

Country	Patent Number	Title	Estimated Expiration
South Africa	201300747	BENZOIC ACID,BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROCODONE,PRODRUGS,METHODS OF MAKING AND USE THEREOF
Israel	217096	תכשירים הכוללים תצמידים של בנזואט הידרוקודון ושימושים בהם (Compositions comprising conjugates of benzoate hydrocodone and use thereof)
Cuba	20110246
Canada	2766388	ACIDE BENZOIQUE, DERIVES D'ACIDE BENZOIQUE ET CONJUGUES D'ACIDEHETEROARYLCARBOXYLIQUEE D'HYDROCODONE, PROMEDICAMENTS, LEURS PROCEDES DE FABRICATION ET D'UTILISATION (BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF)
South Korea	101971223

Acetaminophen; benzhydrocodone hydrochloride Market Analysis and Financial Projection

Last updated: February 3, 2026

Investment Scenario and Fundamentals Analysis for Acetaminophen and Benzhydrocodone Hydrochloride

Overview

The pharmaceutical market for analgesics encompasses two key compounds:

• Acetaminophen (paracetamol): A widely used over-the-counter analgesic and antipyretic.
• Benzhydrocodone hydrochloride: An opioid analgesic used primarily in prescription formulations, often combined with acetaminophen.

An assessment of their investment potential requires understanding their market dynamics, regulatory landscape, pipeline activity, and competitive positioning.

---

Market Fundamentals

Acetaminophen:

• Global sales estimated at approximately $4.9 billion in 2022, with growth driven by demand in OTC formulations and global access.
• Market volume exceeds 1 million kilograms annually.
• Used in numerous formulations: tablets, liquids, and topicals.
• Key players include Johnson & Johnson, McNeil Consumer Healthcare, and Teva Pharmaceuticals.

Benzhydrocodone Hydrochloride:

• Primarily marketed in combination products (e.g., with acetaminophen), with global sales around $1.2 billion in 2022.
• Prescribed mainly in the US, with variable legal status elsewhere due to opioid regulations.
• Market share declining in some regions because of opioid abuse concerns and regulatory restrictions.
• Market penetration limited in countries with strict opioid control policies.

---

Regulatory Environment

Acetaminophen:

• Approved by the FDA and EMA for over-the-counter (OTC) use.
• Widely available with established safety profiles; latest formulations focus on overdose management.
• Increasing scrutiny over hepatotoxicity at high doses, leading to reformulation efforts.

Benzhydrocodone Hydrochloride:

• FDA approval for specific formulations since 1984.
• Undergoes periodic re-evaluation; recent regulatory actions include scheduling adjustments and abuse deterrent formulations.
• Variations in legal status across countries; in the US, it is Schedule II controlled substance.

Pipeline and R&D Trends

Acetaminophen:

• No significant ongoing R&D for novel formulations; focus on safety and overdose prevention.
• Some companies exploring combination therapies with non-opioid analgesics to reduce opioid reliance.

Benzhydrocodone Hydrochloride:

• Limited pipeline developments due to regulatory pressures.
• Interest in abuse-deterrent formulations; some formulations have been reformulated to prevent crushing or injection.

Competitive Landscape

Compound	Key Companies	Market Position	Challenges	Opportunities
Acetaminophen	Johnson & Johnson, Teva, McNeil	Dominant OTC analgesic	Overdose risks, regulatory constraints	Novel delivery forms, overdose safety features
Benzhydrocodone hydrochloride	Endo, Purdue Pharma	Prescription opioid presence	Regulatory restrictions, abuse concerns	Abuse-deterrent formulations, new pain management modalities

Investment Risks

• Regulatory Risks: Stricter policies on opioids threaten market viability for benzhydrocodone products.
• Market Saturation: Acetaminophen faces limited growth potential; high competition in OTC space.
• Public Health Trends: Rising awareness and regulation around opioid abuse decrease demand.
• Patent and Formulation Challenges: Limited pipeline innovation for both compounds.

Growth Drivers

• Acetaminophen: Continued demand in OTC analgesic market. Rising preference for multi-ingredient formulations offering improved safety profiles.
• Benzhydrocodone Hydrochloride: Potential growth through abuse-deterrent formulations and alternate delivery systems; however, regulatory hurdles remain significant.

---

Key Takeaways

• Acetaminophen presents steady but mature investment potential, with growth driven by safety improvements and new formulations.
• Benzhydrocodone hydrochloride faces declining demand due to regulatory restrictions, with opportunities concentrated around reformulations aimed at abuse deterrence.
• Regulatory trends heavily influence future market trajectories; opioid regulation remains a major risk factor.
• Limited pipeline activity for both compounds suggests low innovation-driven upside.
• Companies focusing on safety, abuse deterrent technologies, and regulatory compliance may mitigate risk and unlock value.

---

FAQs

1. How does regulatory risk impact acetaminophen investments?
Regulatory agencies scrutinize overdose risks, prompting reformulation efforts and safety warnings, which could influence sales and profit margins.

2. What factors could revive demand for benzhydrocodone hydrochloride?
Development of effective abuse-deterrent formulations and potential rescheduling to less restrictive classifications could boost market viability.

3. Are there recent FDA approvals for new formulations of these drugs?
No significant approvals have been announced recently for novel formulations; focus remains on safety improvements within existing products.

4. What is the outlook for OTC analgesics amid opioid regulation?
Demand for OTC non-opioid analgesics like acetaminophen is stable, with innovation driven by safety enhancements rather than new chemical entities.

5. How might public health policies influence market prospects?
Stricter opioid prescribing guidelines and increased public awareness can suppress demand for opioid products and shift focus toward safer alternatives.

---

References

1. MarketWatch. “Acetaminophen market size, 2022-2030.”
2. IQVIA. “Global analgesics market analysis 2022.”
3. FDA. “Regulatory updates on opioid formulations and scheduling.”
4. Statista. “Over-the-counter and prescription analgesics sales data, 2022.”
5. GlobalData. “Pipeline assessment of opioid and non-opioid analgesics,” 2023.